Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation (Q28203306)
Jump to navigation
Jump to search
scientific article (publication date: September 2003)
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation |
scientific article (publication date: September 2003) |
Statements
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation (English)
0 references
1 reference
1 reference
1 reference
Paul G. Richardson
Edwin P. Alyea
Richard M. Stone
Robert J. Soiffer
Daniel J. DeAngelo
1 September 2003
0 references
102
0 references
5
0 references
1578-82
0 references
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference